MX2014013664A - N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. - Google Patents

N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.

Info

Publication number
MX2014013664A
MX2014013664A MX2014013664A MX2014013664A MX2014013664A MX 2014013664 A MX2014013664 A MX 2014013664A MX 2014013664 A MX2014013664 A MX 2014013664A MX 2014013664 A MX2014013664 A MX 2014013664A MX 2014013664 A MX2014013664 A MX 2014013664A
Authority
MX
Mexico
Prior art keywords
methyl
dihydroquinoline
carboxamide
oxo
hydroxyl
Prior art date
Application number
MX2014013664A
Other languages
English (en)
Inventor
Konstantin Ulanenko
Avital Laxer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2014013664A publication Critical patent/MX2014013664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención actual proporciona composiciones farmacéuticas que contiene laquinimod o una sal farmacéuticamente aceptable del mismo, un compuesto aislado de N-etil-4-hidroxil-1-metil-5-(metil( 2,3,4,5,6-pentahidroxietil)amino)-2-oxo-N-fenil-1,2-dihidroquinol in-3-carboxamida o una sal del mismo, composiciones que contienen N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-N-fenil-1,2-dihidroquinolin-3-carboxamida y métodos para preparar el mismo.
MX2014013664A 2012-05-08 2013-05-07 N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. MX2014013664A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644054P 2012-05-08 2012-05-08
PCT/US2013/039911 WO2013169746A2 (en) 2012-05-08 2013-05-07 N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide

Publications (1)

Publication Number Publication Date
MX2014013664A true MX2014013664A (es) 2015-04-17

Family

ID=49551433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013664A MX2014013664A (es) 2012-05-08 2013-05-07 N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.

Country Status (19)

Country Link
US (1) US8809537B2 (es)
EP (1) EP2697201A4 (es)
KR (1) KR20150022816A (es)
CN (1) CN104395291B (es)
AR (1) AR090975A1 (es)
AU (1) AU2013259779B2 (es)
BR (1) BR112014028121A2 (es)
CA (1) CA2873258A1 (es)
EA (1) EA201492029A1 (es)
HK (1) HK1207080A1 (es)
IL (1) IL235338A0 (es)
IN (1) IN2014MN02485A (es)
MX (1) MX2014013664A (es)
NZ (1) NZ630549A (es)
SG (1) SG11201407447XA (es)
TW (1) TW201350467A (es)
UY (1) UY34791A (es)
WO (1) WO2013169746A2 (es)
ZA (1) ZA201408825B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
CN104114172A (zh) 2012-02-16 2014-10-22 泰华制药工业有限公司 N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2890194A1 (en) * 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2159804A (en) * 1937-11-23 1939-05-23 Du Pont N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US6043006A (en) * 1997-09-04 2000-03-28 Fuji Photo Film Co., Ltd. 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
CA2376202C (en) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
PT1937642E (pt) 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
WO2007146248A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
KR20120037477A (ko) 2009-06-19 2012-04-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 다발경화증의 치료
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
RS55071B1 (sr) 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
PT2542079E (pt) 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
SG10201501535UA (en) 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
NZ602512A (en) 2010-03-03 2014-07-25 Teva Pharma Treatment of lupus arthritis using laquinimod
EP2597954A4 (en) 2010-07-09 2014-01-01 Teva Pharma DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
JP2012047974A (ja) * 2010-08-26 2012-03-08 Toshiba Corp 映像表示装置及び映像表示方法
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
NZ611628A (en) 2010-12-07 2015-06-26 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2013016684A1 (en) 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
CN103781355A (zh) 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与干扰素-β的组合治疗多发性硬化症
CN103974704A (zh) 2011-10-12 2014-08-06 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Also Published As

Publication number Publication date
WO2013169746A2 (en) 2013-11-14
US8809537B2 (en) 2014-08-19
IN2014MN02485A (es) 2015-07-17
AU2013259779A1 (en) 2014-12-18
EA201492029A1 (ru) 2015-06-30
CN104395291A (zh) 2015-03-04
NZ630549A (en) 2016-01-29
CA2873258A1 (en) 2013-11-14
ZA201408825B (en) 2016-07-27
EP2697201A2 (en) 2014-02-19
WO2013169746A3 (en) 2013-12-05
US20130345256A1 (en) 2013-12-26
SG11201407447XA (en) 2015-02-27
AR090975A1 (es) 2014-12-17
BR112014028121A2 (pt) 2017-06-27
IL235338A0 (en) 2014-12-31
KR20150022816A (ko) 2015-03-04
CN104395291B (zh) 2017-07-28
TW201350467A (zh) 2013-12-16
EP2697201A4 (en) 2014-11-26
HK1207080A1 (en) 2016-01-22
AU2013259779B2 (en) 2017-06-08
UY34791A (es) 2013-11-29

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
MY181898A (en) Heterocyclic compounds and uses thereof
IN2014DN10670A (es)
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
PH12015501609A1 (en) Phenicol antibacterials
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
IN2014DN07996A (es)
UA118562C2 (uk) Модулятори рецептора cxcr7
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
PH12015501056A1 (en) 2-pyridone compound
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
JO2775B1 (en) 3-indazolil 4-pyridyl isothiazole